Adaptive Biotechnologies (ADPT) Stock Statistics & Valuation Metrics

Adaptive Biotechnologies has a market cap or net worth of $1.17B. The enterprise value is $885.48M.

Adaptive Biotechnologies has 148,582,200 shares outstanding. The number of shares has decreased by -2.65% in one year.

Adaptive Biotechnologies’s return on equity (ROE) is -0.79 and return on invested capital (ROIC) is -36.00%.

The current PE Ratio of Adaptive Biotechnologies is -5.53. Adaptive Biotechnologies’s PEG ratio is 0.18.

In the last 12 months, Adaptive Biotechnologies had revenue of 178.96M and earned -159.49M in profits. Earnings per share was -1.08.

In the last 12 months, operating cash flow was -95.21M and capital expenditures -3.66M, giving a free cash flow of -98.88M billion.

Adaptive Biotechnologies pays an annual dividend of ―, resulting in a dividend yield of ―

Adaptive Biotechnologies upcoming earnings date is May 1, 2025, TBA Not Confirmed.

Adaptive Biotechnologies as a current ratio of 2.89, with Debt / Equity ratio of 44.10%

In the past 12 months, Adaptive Biotechnologies has paid 0.00 in taxes.

Adaptive Biotechnologies EV to EBITDA ratio is -7.18, with an EV/FCF ratio of -9.35.

Adaptive Biotechnologies has $222.29M in cash and marketable securities with $0.00 in debt, giving a net cash position of -$132.91M billion.

Gross margin is 58.17%, with operating margin of -90.83%, and net profit margin of -89.12%.

The average price target for Adaptive Biotechnologies is $9.57, which is 11.43% higher than the current price. The consensus rating is Strong Buy